Literature DB >> 10490764

Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors.

K W Peng1, R Vile, F L Cosset, S Russell.   

Abstract

We recently showed that retroviral vectors can be targeted through protease substrate interactions. Infectivity is blocked by a polypeptide fused to the viral envelope glycoprotein (SU) and is restored when a protease cleaves the connecting linker, releasing the inhibitory polypeptide from the viral surface. Protease specificity is achieved by engineering the sequence of the linker. Here, using two different matrix-metalloproteinase (MMP)-activatable vectors, we demonstrated highly efficient and selective transduction of MMP-rich target cells in a heterogeneous cell population. In vivo, the MMP-targeted vectors showed strong selectivity for MMP-rich tumor xenografts. Protease-activatable vectors offer new possibilities for in vivo targeting of gene delivery.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490764     DOI: 10.1038/sj.gt.3300982

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  12 in total

1.  A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor.

Authors:  S Snitkovsky; T M Niederman; B S Carter; R C Mulligan; J A Young
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 2.  Matrix metalloproteases: underutilized targets for drug delivery.

Authors:  Deepali G Vartak; Richard A Gemeinhart
Journal:  J Drug Target       Date:  2007-01       Impact factor: 5.121

Review 3.  Molecular engineering of viral gene delivery vehicles.

Authors:  David V Schaffer; James T Koerber; Kwang-il Lim
Journal:  Annu Rev Biomed Eng       Date:  2008       Impact factor: 9.590

Review 4.  Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy.

Authors:  Megumi Iiizumi; Wen Liu; Sudha K Pai; Eiji Furuta; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2008-07-22

Review 5.  Viral vectors: from virology to transgene expression.

Authors:  D Bouard; D Alazard-Dany; F-L Cosset
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

Review 6.  Physical, chemical, and synthetic virology: Reprogramming viruses as controllable nanodevices.

Authors:  Maria Yanqing Chen; Susan S Butler; Weitong Chen; Junghae Suh
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-11-08

Review 7.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

8.  Targeted retroviral infection of tumor cells by receptor cooperation.

Authors:  Francisco Martin; Simon Chowdhury; Stuart J Neil; Kerry A Chester; Francois-Loic Cosset; Mary K Collins
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 9.  Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded.

Authors:  Roberto Cattaneo; Tanner Miest; Elena V Shashkova; Michael A Barry
Journal:  Nat Rev Microbiol       Date:  2008-07       Impact factor: 60.633

Review 10.  Viral vectors for gene transfer: a review of their use in the treatment of human diseases.

Authors:  W Walther; U Stein
Journal:  Drugs       Date:  2000-08       Impact factor: 11.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.